The purpose of the current study is to see how well liposomal doxorubicin (Doxil) and rituximab work in combination with cyclophosphamide, vincristine, and prednisone (DR-COP) in shrinking tumors in patients with AIDS-related NHL. The combination of liposomal doxorubicin and rituximab with cyclophosphamide, vincristine, and prednisone (all part of the standard R-CHOP treatment, in which only the doxorubicin is given in the liposome) is an experimental treatment, called “DR-COP”.

During this study, patients will be followed closely during and after therapy to see how well their cancer is controlled by the chemotherapy treatment, how the treatment affects theirr HIV illness, what side effects result and how patients tolerate the treatment.

Inclusion Criteria:

• Men and women 18 years or older
• Documented HIV infection
• Laboratory tests within acceptable ranges for study inclusion.
• Currently on antiretroviral therapy for HIV
• Previously untreated B-cell non-Hodgkin's lymphoma

Exclusion criteria:

• Primary central nervous system lymphoma
• Presence of second active tumor other than KS, cervical carcinoma or non-melanoma skin cancer
• Known pregnancy or breast feeding
• Expected survival less than two months

This study is being conducted by Dr. Ronald Mitsuyasu under IRB #06-10-095-01

If you think you might be interested in participating in this study, please contact Deon Claiborne at 310-557-9062 or email at dclaiborne@mednet.ucla.edu

Return to Clinical Trials main page